MS023 treatment inhibited the methyltransferase activity of PRMT1 in leukemia cells from CML mice as reflected by the decreased protein level of H4R3me2a (Figure S7O, Supporting Information). This evidence concerns the gene PRMT1 and chronic myelogenous leukemia, BCR-ABL1 positive.